Distal ventricular pacing and intraventricular gradient reduction for symptomatic relief in drug-refractory hypertrophic cardiomyopathy patients with mid-cavity obstruction

Queen Mary University of London0 个研究点目标入组 25 人开始时间: 2018年1月11日最近更新: 2021年10月4日

适应症

试验速览

暂无简介。

•1. Male or female, >18 years
•2. Referred for PPM +/- ICD implantation for either primary prevention of sudden cardiac death or other indications such as heart block or obstructive physiology
•3. HCM patients with a mid-cavity gradient of =30 mmHg demonstrated by echocardiography and morphology confirmed by cardiac MRI. Gradient confirmed by cardiac catheterisation
•4. All patients should be taking maximum tolerated doses of beta blockers or verapamil with or without disopyramide
•5. Symptoms refractory to optimum medical therapy as above, for example breathlessness, chest pain, dizziness, or syncope

•1. Patients with multi-level obstruction, i.e. across the mid-cavity and outflow tract
•2. Patients with moderate or severe valvular stenosis or regurgitation due to primary valvular disease
•3. Patients with untreated symptomatic coronary disease
•4. Patients in atrial fibrillation at the time of implantation
•5. Pregnancy
•6. Renal failure with eGFR < 20mL/min
•7. Any patient not suitable in the clinicians opinion
•8. Any patient who is for whatever reason is not expected for more than one year
•9. Patients unable to provide informed consent

发起方